GlassScriptPhysician profile
Thu Van Tran
NPI 1700476280
$4,641.26
in general payments reported to CMS, 2019-2025
30 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $850 · 2023: $835 · 2024: $960 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $717.12 | 2021-2025 | Livdelzi |
| Lilly USA, LLC | $532.53 | 2021-2025 | Jardiance, Zepbound, Emgality |
| Abbvie INC. | $408.11 | 2022-2025 | |
| Amgen INC. | $394.32 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $362.82 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $316.72 | 2021-2025 | Breztri, Fasenra, Farxiga |
| Amarin Pharma, INC. | $253.46 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.06 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.92 | 2021-2025 | Jardiance, Jascayd |
| Abbott Laboratories | $209.36 | 2021-2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $170.74 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $124.68 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.75 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $73.39 | 2023-2025 | Shingrix, Arexvy |
| Lundbeck LLC | $72.54 | 2023-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $61.71 | 2022-2023 | Livalo, Seglentis |
| Verity Pharmaceuticals INC. | $58.17 | 2024-2025 | Tlando |
| Redhill Biopharma INC. | $55.52 | 2021-2024 | Talicia |
| Merck Sharp & Dohme LLC | $53.27 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Corcept Therapeutics | $42.92 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $35.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.34 | 2022 | |
| Biotronik INC. | $22.19 | 2021 | |
| Antares Pharma, INC. | $22.12 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $20.84 | 2024 | |
| Exact Sciences Corporation | $17.43 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $15.27 | 2025 | |
| Currax Pharmaceuticals LLC | $14.24 | 2023 | Onzetra Xsail, Contrave |
| Lucid Diagnostics INC. | $13.70 | 2022 | |
| Dynavax Technologies Corporation | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu Van Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.